Treatment of acute myeloid leukemia in children
https://doi.org/10.17650/1818-8346-2006-0-1-2-63-70
Abstract
The results of treatment in children with acute myeloid leukemia (AML) have considerably improved in the past 15 years. Whether cranial irradiation, maintenance therapy, and hematopoietic stem cell transplantation should be used during the first remission remains unclear. This paper presents the histo- ry of development of AML treatment in children, the potentialities of current chemotherapy, and indications for allogenic and autologous hemopoietic stem cell transplantation in accordance with the data obtained by different groups of investigators, including ones from Russia. The Institute of Pediatric Oncology and Hematology (IPOH), Russian Cancer Research Cancer, Russian Academy of Medical Sciences, has developed and introduced an IPOH AML proto- col in 2002. From July 2002 to January 2006, 40 patients were enrolled in this study and stratified into 3 risk groups: 1) a standard risk group (n = 10 — 28.6%)); 2) an intermediate risk group (17 — 48,6%), and 3) a high risk group (n = 8 — 22.9%). Three-year relapse-free survival was 40±12%.
About the Authors
A. V. Popa
Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
S. A. Mayakova
Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Moscow
References
1. Choi S.I., Simone J.V. Acute nonlymphocytic leukemia in 171 children. Med Pediatr Oncol 1976;2:119–76.
2. Van Der Does-Van Den Berg A., Van Wering E.R., Van Zanen C.E. Acute nietlympfatischen leukemieen bij kinderen in Nederland (1972-1977). Tijdschr Kindergeneeskd 1978;46:146–53.
3. Chard Jr. Rl., Frankleshtein J.Z., Sonley M.J. et al. Increased survival in childhood nonlymphocytic leukemia after treatment with prednisone cytosine arabinoside, 6-thioguanine, cyclophosphomide, and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol 1978;4:263–73.
4. Weinshtein H.J., Mayer R.J., Rosental D.S. et al. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980;303:473–8.
5. Riehm H., Gadner H., Welte K. Die West-Berliner Studie zur Behanlung der akuten lymphoblastishen Leukamie des Kindes – Erfandlungsbericht nach 6 Jahren. Klin Padiatr 1977;189:89–102.
6. Baehner R.J., Bernstein I.D., Sather et al. Improved remission induction rate D-ZAPO but unimproved remission duration with addition of immutherapy to chemotherapy in previously untreated children with ANLL. Med Pediatr Oncol 1979;7:127–39.
7. Buchner T., Urbanitz D., Hiddemann W. et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of German AML Cooperative Group. J Clin Oncol 1985;3:1583–9.
8. Creutzig U., Zimmermann M., Ritter J. et al. Treatment strategies and longterm in pediatric patients treated in four consecutive AML-BFM trails. Leukemia 2005;19:2039–42.
9. Carella A.M., Berman E., Maraone M.P., Ganzina F. An overview of preclinical and clinical studies. Hematologica 1990;75:159–69.
10. Berman E., McBride M.. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:3267–73.
11. Creutzig U., Ritter J., Zimmermann M. et al. for the BFM study group. Idarubicine improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001;15:348–54.
12. Creutzig U., Berhold F., Boos J. et al. Improved treatment results in children with AML: results of study AML-BFM 93. Klin Pediatr 2001;213:175–85.
13. Creutzig U., Ritter J., Schelong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AMLBFM-83 as a compared with study AMLBFM-78. Blood 1990;75:1932–40.
14. Gibson B.E.S., Wheatley K., Hann I.M. et al. Treatment strategy and longterm results in pediatric patients treated in consecutive UK AML trais. Leukemia 2005;19:2130–8.
15. Perel Y., Auvrignon A., Leblanc T. et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no beneit – multicenter studies of the French LAME (Leucemie Aiguё Myelobalstique Enfant) Cooperative Group. Leukemia 2005;19:2082–9.
16. Smith O., Alonzo T.A., Gerbing R.B. et al. Long-term results of children with acute myeloid leukemia: report of three consecutive Phase III trails by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005;19 – pp. 2054–62.
17. Wells R.J., Woods W.G., Buckley J.D. et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Children’s cancer Group study. J Clin Oncol 1994;12:2367–77.
18. Woods W.G., Kobrinsky N., Buckley J.D. et al. Timed sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from Children’s Cancer Group. Blood 1996;87: 4979–89.
19. Woods W.G., Neudorf S., Gold S. et al. A comparison of allogenic bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from Children’s Cancer Group. Blood 2001;97: 56–62.
20. Ribeiro R.C., Razzouk B.I., Pounds S. et al. Successive clinical trails for childhood acute myeloid leukemia at St Jude Children’s Research Hospital, from 1980 to 2000. Leukemia 2005;19:2125–9.
21. Попа А.В., Маякова С.А., Тупицын Н.Н. Прогностическое значение иммунологических маркеров острого нелимфобластного лейкоза у детей. Педиатрия 1999;(3).
22. Попа А.В., Маякова С.А., Тупицын Н.Н. Результаты лечения детей, больных острым миелоидным лейкозом, в зависимости от иммунофенотипа бластных клеток. Гематол и трансфузиол 1999;(6).
23. Abbott B.L, Rubnitz J.E., Tong X. et al. Clinical significance of central of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution’s experience. Leukemia 2003;17:2090–6.
24. Creutzig U., Zimmermann M., Reinhardt D. et al. Early death and treatment related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trails AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384–93.
25. Lehnbecher T., Varwig D., Kaiser J. et al. Infectious complications in pediatric acute myeloid leukemia: analisis of the prospective multi-institutional clinical trail AML-BFM 93. Leukemia 2004;18:72–7.
26. Slats A.M., Egeler R.M., Van Der Does-Van den Berg A. et al. Causes of death other then progressive leukemia in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005;19:537–44.
27. Creutzig U., Reinhardt D. Currant controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation? A European view. Br J Hematol 2002;118:365–77.
28. Chen A.R., Alonzo T.A., Woods W.G., Arceci R.J. Currant controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation? An American view. Br J Hematol 2002;118:378–84.
29. Whealthy K. Currant controversies: which patients with acute myeloid leukemia should receive a bone marrow transplantation? A statistician view. Br J Hematol 2002;118:351–56.
Review
For citations:
Popa A.V., Mayakova S.A. Treatment of acute myeloid leukemia in children. Oncohematology. 2006;(1-2):63-70. (In Russ.) https://doi.org/10.17650/1818-8346-2006-0-1-2-63-70
Views:
142
Email this article 